MedTrace Logo

Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms

NCT05000346 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2023-01-06

No results posted yet for this study

Summary

Double-blind parallel trial to assess the efficacy and safety of inhaled AQ001S in the management of acute COVID-19 symptoms compared.

Conditions

  • Covid19

Interventions

DRUG

Drug, inhalation

Solution administered by inhalation

Sponsors & Collaborators

  • Aquilon Pharmaceuticals S.A.

    lead INDUSTRY

Principal Investigators

  • Julien Guiot, MD · Centre Hospitalier Universitaire de Liege

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-04
Primary Completion
2022-12-21
Completion
2022-12-21

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05000346 on ClinicalTrials.gov